FR2915100B1 - Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson - Google Patents

Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson

Info

Publication number
FR2915100B1
FR2915100B1 FR0702853A FR0702853A FR2915100B1 FR 2915100 B1 FR2915100 B1 FR 2915100B1 FR 0702853 A FR0702853 A FR 0702853A FR 0702853 A FR0702853 A FR 0702853A FR 2915100 B1 FR2915100 B1 FR 2915100B1
Authority
FR
France
Prior art keywords
carboxalide
oxydo
cyclopropylmethoxy
pyridin
parkinson
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0702853A
Other languages
English (en)
French (fr)
Other versions
FR2915100A1 (fr
Inventor
Goyet Philippe Delay
Claire Delgorge
Christine Menet
Gilles Poughon
Trillou Christine Ravinet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to FR0702853A priority Critical patent/FR2915100B1/fr
Priority to PA20088776801A priority patent/PA8776801A1/es
Priority to MYPI20094343A priority patent/MY148092A/en
Priority to CA2684174A priority patent/CA2684174C/fr
Priority to RS20110358A priority patent/RS51869B/sr
Priority to BRPI0810444A priority patent/BRPI0810444A2/pt
Priority to JP2010503549A priority patent/JP5386478B2/ja
Priority to KR1020147033000A priority patent/KR20150004885A/ko
Priority to AU2008257322A priority patent/AU2008257322B2/en
Priority to HR20110666T priority patent/HRP20110666T1/hr
Priority to MEP-2009-299A priority patent/ME00935B/me
Priority to AT08787963T priority patent/ATE513548T1/de
Priority to EP08787963A priority patent/EP2146714B1/fr
Priority to PL08787963T priority patent/PL2146714T3/pl
Priority to CN2008800126498A priority patent/CN101663035B/zh
Priority to NZ580482A priority patent/NZ580482A/en
Priority to KR1020097021593A priority patent/KR101503942B1/ko
Priority to MX2009011284A priority patent/MX2009011284A/es
Priority to PCT/FR2008/000534 priority patent/WO2008145841A1/fr
Priority to HK10108261.3A priority patent/HK1141725B/xx
Priority to SI200830357T priority patent/SI2146714T1/sl
Priority to DK08787963.1T priority patent/DK2146714T3/da
Priority to PT08787963T priority patent/PT2146714E/pt
Priority to EA200970970A priority patent/EA019194B1/ru
Priority to ES08787963T priority patent/ES2367408T3/es
Priority to JO2008182A priority patent/JO2678B1/en
Priority to TW097113997A priority patent/TWI439269B/zh
Priority to UY31035A priority patent/UY31035A1/es
Priority to CL2008001136A priority patent/CL2008001136A1/es
Priority to ARP080101602A priority patent/AR066108A1/es
Publication of FR2915100A1 publication Critical patent/FR2915100A1/fr
Application granted granted Critical
Publication of FR2915100B1 publication Critical patent/FR2915100B1/fr
Priority to US12/573,326 priority patent/US20100130554A1/en
Priority to IL201448A priority patent/IL201448A/en
Priority to ZA2009/07251A priority patent/ZA200907251B/en
Priority to MA32333A priority patent/MA31367B1/fr
Priority to CY20111100887T priority patent/CY1111840T1/el
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
FR0702853A 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson Expired - Fee Related FR2915100B1 (fr)

Priority Applications (35)

Application Number Priority Date Filing Date Title
FR0702853A FR2915100B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson
PA20088776801A PA8776801A1 (es) 2007-04-19 2008-04-15 Utilización de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de trastornos motores asociados a la enfermedad de parkinson.
SI200830357T SI2146714T1 (sl) 2007-04-19 2008-04-16 Uporaba 4-ciklopropilmetoksi-N-(3,5-dikloro-1-oksido-piridin-4-il)-5-(metoksi) priridin-2-karboksamida za zdravljenje motoričnih motenj, povezanih s Parkinsonovo boleznijo
RS20110358A RS51869B (sr) 2007-04-19 2008-04-16 Upotreba 4-ciklopropilmetoksi-n-(3,5-dihloro-1-oksido-piridin-4-il)-5- (metoksi)piridin-2-karboksamida za lečenje motornih poremećaja vezanih za parkinsonovu bolest
BRPI0810444A BRPI0810444A2 (pt) 2007-04-19 2008-04-16 utilização da 4-ciclopropil metóxi-n-(3,5-dicloro-1-óxido-4-piridin-4-il)-5-(metóxi)piridina-2-carboxamida para o tratamento dos distúrbios motores ligados ao mal de parkinson
JP2010503549A JP5386478B2 (ja) 2007-04-19 2008-04-16 パーキンソン病に伴う運動不全の治療のための４−シクロプロピルメトキシ−ｎ−（３，５−ジクロロ−１−オキシドピリジン−４−イル）−５−（メトキシ）ピリジン−２−カルボキサミドの使用
KR1020147033000A KR20150004885A (ko) 2007-04-19 2008-04-16 파킨슨병과 관련된 운동 장애의 치료를 위한 4-시클로프로필메톡시-ｎ-(3,5-디클로로-1-옥시도피리딘-4-일)-5-(메톡시)피리딘-2-카르복스아미드의 용도
AU2008257322A AU2008257322B2 (en) 2007-04-19 2008-04-16 Use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to Parkinson's disease
HR20110666T HRP20110666T1 (hr) 2007-04-19 2008-04-16 Uporaba 4-ciklopropilmetoksi-n-(3,5-diklor-1-oksidopiridin-4-il)-5-(metoksi)piridin-2-karboksamida u liječenju motoričkih poremećaja povezanih s parkinsonovom bolesti
MEP-2009-299A ME00935B (me) 2007-04-19 2008-04-16 Upotreba 4-ciklopropilmetoksi-<i>n</i>-(3,5-dihlor0-1- 0ksido- piridin-4-il)-5-(metoksi)piridin-2- karboksamida za liječenje motoričkih poremećaja povezanih sa parkinsonovom bolešću
PT08787963T PT2146714E (pt) 2007-04-19 2008-04-16 Utilização de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxidopiridin- 4-il)-5-(metoxi)piridina-2-carboxamida para o tratamento dos distúrbios motores relacionados com a doença de parkinson
EP08787963A EP2146714B1 (fr) 2007-04-19 2008-04-16 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson
PL08787963T PL2146714T3 (pl) 2007-04-19 2008-04-16 Zastosowanie 4-cyklopropylometoksy-n-(3,5-dichloro-1-tlenek-pirydyn-4-ylo)-5-(metoksy)pirydyno-2-karboksyamidu do leczenia zaburzeń ruchowych związanych z chorobą parkinsona
CN2008800126498A CN101663035B (zh) 2007-04-19 2008-04-16 4-环丙基甲氧基-n-(3，5-二氯代-1-氧化-吡啶-4-基)-5-(甲氧基)吡啶-2-甲酰胺在制备用于治疗与帕金森症有关的运动障碍的药物中的用途
NZ580482A NZ580482A (en) 2007-04-19 2008-04-16 Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease
KR1020097021593A KR101503942B1 (ko) 2007-04-19 2008-04-16 파킨슨병과 관련된 운동 장애의 치료를 위한 4-시클로프로필메톡시-ｎ-(3,5-디클로로-1-옥시도피리딘-4-일)-5-(메톡시)피리딘-2-카르복스아미드의 용도
MX2009011284A MX2009011284A (es) 2007-04-19 2008-04-16 Uso de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-piridin-4-il)-5- (metoxi)piridin-2-carboxamida para el tratamiento de trastornos motores asociados a la enfermedad de parkinson.
PCT/FR2008/000534 WO2008145841A1 (fr) 2007-04-19 2008-04-16 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson
MYPI20094343A MY148092A (en) 2007-04-19 2008-04-16 Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease
DK08787963.1T DK2146714T3 (da) 2007-04-19 2008-04-16 Anvendelse af 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridin-2-carboxamid til behandling af motoriske forstyrrelser i forbindelse med Parkinsons sygdom
CA2684174A CA2684174C (fr) 2007-04-19 2008-04-16 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson
AT08787963T ATE513548T1 (de) 2007-04-19 2008-04-16 Verwendung von 4-cyclopropylmethoxy-n-(3,5- dichlor-1-oxidopyridin-4-yl)-5-(methoxy-)pyridi - 2-carboxamid zur behandlung motorischer störungen aufgrund der parkinsonschen krankheit
EA200970970A EA019194B1 (ru) 2007-04-19 2008-04-16 Применение 4-циклопропилметокси-n-(3,5-дихлор-1-оксидопиридин-4-ил)-5-(метокси)пиридин-2-карбоксамида для лечения моторных нарушений, связанных с болезнью паркинсона
ES08787963T ES2367408T3 (es) 2007-04-19 2008-04-16 Utilización de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de los trastornos motores asociados a la enfermedad de parkinson.
HK10108261.3A HK1141725B (en) 2007-04-19 2008-04-16 Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for preparing a medicament in the treatment of motor disorders related to parkinson's disease
JO2008182A JO2678B1 (en) 2007-04-19 2008-04-17 Use of 4-methoxy-propyl-3,5-N-dichloro-1-oxido-pyridine-4-yl-5 (methoxy) pyridine-2-carboxamide in the treatment of movement disorders associated with Parkinson's disease
TW097113997A TWI439269B (zh) 2007-04-19 2008-04-17 ４－環丙基甲氧基－ｎ－（３，５－二氯－１－氧離子基吡啶－４－基）－５－（甲氧基）吡啶－２－甲醯胺於製備用於治療與帕金森氏病有關之運動障礙症的藥物之用途
UY31035A UY31035A1 (es) 2007-04-19 2008-04-18 Utilizacion de 4-ciclopropilmetoxi-n-(3,5)-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de trastornos motores asociados a la enfermedad de parkinson
CL2008001136A CL2008001136A1 (es) 2007-04-19 2008-04-18 Uso de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida, en forma de hidrato, solvato, base o sal de adicion a un acido, para preparar un medicamento util en el tratamiento de trastornos motores asociados a la enfermedad de parkinson, tales como, bradiquinesia, discapacidad al caminar y disfagia.
ARP080101602A AR066108A1 (es) 2007-04-19 2008-04-18 Utilizacion de 4- ciclopropilmetoxi -n- (3,5- dicloro-1 oxido- piridin- 4-il) -5-(metoxi) piridin-2- carboxamida para el tratamiento de trastornos motores asociados a la enfermedad de parkinson
US12/573,326 US20100130554A1 (en) 2007-04-19 2009-10-05 Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease
IL201448A IL201448A (en) 2007-04-19 2009-10-11 Use of 4 - cyclopropylmethoxy - n - (3, 5 - dichloro - 1 - oxydopyridine - 4 - il) - 5 - (methoxy) pyridine - 2 - carboxamide for the preparation of a drug for motor disorders associated with Parkinson's disease
ZA2009/07251A ZA200907251B (en) 2007-04-19 2009-10-16 Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease
MA32333A MA31367B1 (fr) 2007-04-19 2009-11-10 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson.
CY20111100887T CY1111840T1 (el) 2007-04-19 2011-09-15 Χρηση του 4-κυκλοπροπυλμεθοξυ-ν-(3,5-διχλωρο-1-οξειδο-πυριδιν-4-υλ)-5-(μεθοξυ)πυριδιν-2-καρβοξαμιδιου για τη θεραπεια κινητικων διαταραχων που σχετιζονται με τη νοσο toy parkinson

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0702853A FR2915100B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson

Publications (2)

Publication Number Publication Date
FR2915100A1 FR2915100A1 (fr) 2008-10-24
FR2915100B1 true FR2915100B1 (fr) 2009-06-05

Family

ID=38712405

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0702853A Expired - Fee Related FR2915100B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson

Country Status (33)

Country Link
US (1) US20100130554A1 (OSRAM)
EP (1) EP2146714B1 (OSRAM)
JP (1) JP5386478B2 (OSRAM)
KR (2) KR101503942B1 (OSRAM)
CN (1) CN101663035B (OSRAM)
AR (1) AR066108A1 (OSRAM)
AT (1) ATE513548T1 (OSRAM)
AU (1) AU2008257322B2 (OSRAM)
BR (1) BRPI0810444A2 (OSRAM)
CA (1) CA2684174C (OSRAM)
CL (1) CL2008001136A1 (OSRAM)
CY (1) CY1111840T1 (OSRAM)
DK (1) DK2146714T3 (OSRAM)
EA (1) EA019194B1 (OSRAM)
ES (1) ES2367408T3 (OSRAM)
FR (1) FR2915100B1 (OSRAM)
HR (1) HRP20110666T1 (OSRAM)
IL (1) IL201448A (OSRAM)
JO (1) JO2678B1 (OSRAM)
MA (1) MA31367B1 (OSRAM)
ME (1) ME00935B (OSRAM)
MX (1) MX2009011284A (OSRAM)
MY (1) MY148092A (OSRAM)
NZ (1) NZ580482A (OSRAM)
PA (1) PA8776801A1 (OSRAM)
PL (1) PL2146714T3 (OSRAM)
PT (1) PT2146714E (OSRAM)
RS (1) RS51869B (OSRAM)
SI (1) SI2146714T1 (OSRAM)
TW (1) TWI439269B (OSRAM)
UY (1) UY31035A1 (OSRAM)
WO (1) WO2008145841A1 (OSRAM)
ZA (1) ZA200907251B (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016500094A (ja) * 2012-11-28 2016-01-07 サノフイ ４−（シクロプロピルメトキシ）−ｎ−（３，５−ジクロロ−１−オキシドピリジン−４−イル）−５−メトキシピリジン−２−カルボキサミドの結晶形態の製造方法およびその結晶形態
US9624100B2 (en) 2014-06-12 2017-04-18 Apple Inc. Micro pick up array pivot mount with integrated strain sensing elements
WO2025079694A1 (ja) * 2023-10-12 2025-04-17 株式会社 メドレックス 経皮吸収組成物
US20250120957A1 (en) * 2023-10-12 2025-04-17 Alto Neuroscience, Inc. Treatment of neuropsychiatric disorders with tilivapram

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
JP3775685B2 (ja) * 1993-07-28 2006-05-17 ローン−プーラン・ロレ・リミテツド Ｐｄｅ▲ｉｖ▼およびｔｎｆ抑制剤としての化合物
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
PT1244649E (pt) * 1999-12-23 2005-06-30 Icos Corp Inibidores de fosfodiesterase especificos de mfa ciclica
HUP0600103A2 (en) * 2001-03-02 2006-06-28 Bristol Myers Squibb Co Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
JP2005538972A (ja) * 2002-07-02 2005-12-22 メルク フロスト カナダ アンド カンパニー ジアリール置換エタンピリドンｐｄｅ４阻害剤
ES2362484T3 (es) * 2003-03-12 2011-07-06 Celgene Corporation Compuestos de ácido n-alquil-hidroxámico-isoindolilo y sus usos farmacéuticos.
AU2006257863A1 (en) * 2005-06-10 2006-12-21 F. Hoffmann-La Roche Ag Trisubstituted amines as phosphodiesterase 4 inhibitors
US20070021451A1 (en) * 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury

Also Published As

Publication number Publication date
EA019194B1 (ru) 2014-01-30
KR20150004885A (ko) 2015-01-13
NZ580482A (en) 2011-10-28
DK2146714T3 (da) 2011-10-10
AU2008257322A1 (en) 2008-12-04
EA200970970A1 (ru) 2010-02-26
BRPI0810444A2 (pt) 2016-05-31
JP5386478B2 (ja) 2014-01-15
KR101503942B1 (ko) 2015-03-18
CA2684174C (fr) 2014-02-25
EP2146714A1 (fr) 2010-01-27
KR20090130059A (ko) 2009-12-17
WO2008145841A1 (fr) 2008-12-04
AU2008257322B2 (en) 2013-06-13
MA31367B1 (fr) 2010-05-03
RS51869B (sr) 2012-02-29
MY148092A (en) 2013-02-28
JP2010524906A (ja) 2010-07-22
PT2146714E (pt) 2011-09-02
AR066108A1 (es) 2009-07-22
PA8776801A1 (es) 2008-11-19
CL2008001136A1 (es) 2009-01-16
IL201448A0 (en) 2010-05-31
TWI439269B (zh) 2014-06-01
HRP20110666T1 (hr) 2011-10-31
FR2915100A1 (fr) 2008-10-24
CA2684174A1 (fr) 2008-12-04
JO2678B1 (en) 2013-03-03
ATE513548T1 (de) 2011-07-15
SI2146714T1 (sl) 2011-10-28
ZA200907251B (en) 2011-04-28
UY31035A1 (es) 2008-11-28
ME00935B (me) 2012-06-20
US20100130554A1 (en) 2010-05-27
TW200911247A (en) 2009-03-16
CN101663035A (zh) 2010-03-03
MX2009011284A (es) 2009-11-02
CY1111840T1 (el) 2015-10-07
HK1141725A1 (en) 2010-11-19
EP2146714B1 (fr) 2011-06-22
PL2146714T3 (pl) 2011-10-31
ES2367408T3 (es) 2011-11-03
IL201448A (en) 2014-08-31
CN101663035B (zh) 2012-06-20

Similar Documents

Publication Publication Date Title
FR19C1005I1 (fr) Nano-corps ameliores (tm) pour le traitement des troubles lies a l&#39;agregation
EP2063889A4 (en) SPIROPIPERIDINE BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
EP1838320A4 (en) CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL PROBLEMS
FR13C0029I2 (fr) Compositions pour le traitement de troubles gastro-intestinaux
EP1951273A4 (en) USE OF LACTOBACILLUS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
MA28481B1 (fr) Dérivés d&#39;imidazole pour le traitement de troubles neurodégénératifs
EP2269646A4 (en) PROPHYLACTIC OR THERAPEUTIC ACTIVE AGAINST DIABETES OR ADIPOSITAS
ZA201003965B (en) 1,2,4-oxadiazole compounds for the treatment of autoimmune diseases
MA31798B1 (fr) Composés organiques
EP2306830A4 (en) USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHER LATERAL SCLEROSIS
EP2379075A4 (en) TRIAZOL DERIVATIVES FOR THE TREATMENT OF ALZHEIMER DISEASE
FR2902010B1 (fr) Utilisation de la 1,7 dimethylxanthine pour la fabrication d&#39;un medicament psychoanaleptique non anxiogene destine au traitement d&#39;un trouble neuropsychiatrique
FR2915100B1 (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson
EP2398789A4 (en) SPIROPYRROLIDINE DERIVATIVES AS BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
EP1773970A4 (en) LUBRICANT FORMULATIONS FOR PANEL PROCESSING
EP2207516A4 (en) DEVICE FOR TREATING VAGINAL FUNGI INFECTIONS
FR2918282B1 (fr) Medicament pour le traitement de la maladie de parkinson
FR2907011B1 (fr) Utilisation de la citrulline pour le traitement des etats de denutrition
EP1750513A4 (en) USE OF GPCR54 LIGANDS FOR THE TREATMENT OF BARRENESS
EP1889618A4 (en) Combined drug for treating diabetes
EP2026659A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER
FR2906468B1 (fr) Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques
EP2517698A4 (en) ACTIVE AGENT FOR THE TREATMENT OF MORBUS PARKINSON
FR2918281B1 (fr) Medicament pour le traitement de la maladie de parkinson.
FR2926023B1 (fr) Utilisation d&#39;une homoproteine de la famille bicoid pour le traitement du glaucome.

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 9

ST Notification of lapse

Effective date: 20161230